Tactile Systems Updates 2025 Revenue Forecast to $309M-$315M Following Strategic Investments

Earnings Call Insights: Tactile Systems Technology (TCMD) Q1 2025

Management View

• CEO Sheri Dodd highlighted that total revenue for Q1 2025 grew slightly by 0.3% year-over-year to $61.3 million. However, lymphedema revenue decreased by 3% to $50.6 million, while airway clearance revenue showed strong growth of 22% to $10.7 million.
• Key factors affecting lymphedema performance included a strategic salesforce optimization initiative that temporarily reduced sales headcount and productivity impacts from the implementation of a new Salesforce CRM module.
• The management highlighted continuous investment in growing their sales team, aiming to have 285 representatives by the second quarter’s end and more than 300 by year-end, which would be an all-time high for the firm.
• The company revised full-year 2025 revenue guidance to $309 million to $315 million, reflecting adjustments due to short-term impacts of sales vacancies and CRM adoption challenges.
• CFO Elaine Birkemeyer reported that gross margins improved by 290 basis points year-over-year to 74%, attributed to lower manufacturing and warranty costs.

Outlook

• Full-year 2025 revenue guidance was revised to $309 million to $315 million, reflecting 5% to 8% growth year-over-year.
• The income from airway clearance methods is projected to increase by 20% to 23% this year, thanks to the robust performance of AffloVest and key alliances with durable medical equipment partners.
• The forecasted Adjusted EBITDA for 2025 is expected to range from $32 million to $34 million, concurrent with continuous investments in sales and technology sectors.

Financial Results

• The total income for the first quarter of 2025 amounted to $61.3 million. The lymphedema product line generated $50.6 million, with an additional $10.7 million coming from airway clearance items.
• The operating expenses rose by $3.5 million to reach $49.9 million, largely because of increased reimbursements and greater general and administrative expenditures, which were mainly fueled by investments in technology.
• The firm concluded the quarter with $83.6 million in cash, a decrease from $94.4 million at the close of Q4 2024, attributed to share buybacks and additional bonuses paid out.
• For the quarter, Adjusted EBITDA resulted in a loss of $0.3 million contrasted with an income of $1 million during the same period last year.

Q&A

• Andrew Margaret Kaczor, William Blair questioned the underlying assumptions of the updated revenue guidance. In response, CFO Birkemeyer clarified that this guidance takes into account the rate at which sales positions are being filled and the implementation of the new CRM system. These factors are anticipated to boost productivity during the latter part of the year.
• Ryan Zimmerman from BTIG asked about the profit and loss leverage anticipated for 2026. In response, CFO Birkemeyer stated that the increase in operational expenses for 2025 includes significant one-off expenditures related to technological upgrades. These costs won’t be repeated at the same level, which should enable better financial leveraging in 2026.
• Kyle Bauser from B. Riley Securities asked about the growth of AffloVest and how it impacts profitability. The CEO, Dodd, stressed that AffloVest continues to be beneficial for the company’s financials and pointed out strategic alliances with durable medical equipment (DME) partners as key factors driving expansion.

Sentiment Analysis

• Experts voiced worries regarding the immediate effects of adopting CRM systems and dealing with gaps in their sales team. However, they remained hopeful about the firm’s long-range development prospects as well as its wise financial commitments for future expansion.
• The management expressed confidence when talking about their long-term expansion plans but admitted there were difficulties during the initial part of the year because of necessary operational changes.
• When compared to the prior quarter, there was a noticeable focus on tackling issues related to tactical implementation and a more reserved outlook on near-term income expansion.

Quarter-over-Quarter Comparison

• The pace of revenue growth slowed down as compared to Q4 2024, when there was a 10.2% rise year over year.
• The forecasted revenue guidance for 2025 has been adjusted downwards from an initial range of $316 million to $322 million reported in Q4 2024 to a new estimate between $309 million and $315 million. This change reflects modifications in expected sales force efficiency and altered recruitment schedules.
• Investments in technology and human capital intensified, contrasting with the previous quarter’s focus on gross margin improvements and channel diversification.

Risks and Concerns

• Management identified short-term risks associated with CRM adoption and salesforce coverage gaps.
• Analysts raised concerns about potential delays in achieving full salesforce productivity and the implications for near-term revenue growth.
• The firm is closely tracking the effects of tariffs and implementing measures to reduce their impact, with possible financial repercussions noted for the year 2025.

Final Takeaway

Tactile Systems Technology acknowledged operational challenges in Q1 2025, particularly in the lymphedema segment, but remains committed to its long-term growth strategy through targeted salesforce expansion and technological investments. The revised guidance reflects these short-term headwinds, while strong performance in the airway clearance business and strategic initiatives signal potential for sustained growth in the back half of 2025 and beyond.

Read the full Earnings Call Transcript